IRVINE, Calif., Oct. 16, 2007 (PRIME NEWSWIRE) -- A comprehensive report focusing on MIV Therapeutics Inc. (OTCBB:MIVT) and developments in cardiovascular stents and drug delivery has been published by financial courier StockUpTicks.com and is available free of charge to the general public.
The report will feature detailed information regarding MIVT and address related information and companies including Johnson & Johnson (NYSE:JNJ), Medtronic Inc. (NYSE:MDT), and Boston Scientific (NYSE:BSX).
"With the enormous demographic of aging Baby Boomers hitting their health care years investors are looking closely at the sector," stated SmallCap Sentinel analyst D.R. Clark. "Couple that economic reality with the advent of technology that this report details and the result is most intriguing."
To view the report in its entirety, please visit: http://www.stockupticks.com/profiles/10-16-07.html
MIV Therapeutics Inc., ("MIV") ("MIVT") is focused on commercializing the next generation of fully biocompatible coatings for cardiovascular stents and drug delivery systems to treat coronary artery disease, an estimated $6 billion worldwide market. MIVT's uniquely biocompatible drug delivery technologies for cardiovascular stents are designed to offer a safer alternative to current drug-eluting stents and to solve the issues of late thrombosis.
MIV has recently acquired Biosync Scientific in India and earlier, SagaX in Israel to significantly expand product offerings, as well as design, manufacturing and distribution capabilities.
Working since 2001 in close collaboration with The University of British Columbia (UBC), MIVT has developed a unique biocompatible nano-film coating that eliminates the side-effects attributed to current stent technology. This is a major breakthrough, which utilizes Hydroxyapatite (HAp), a mineral and major component of human bones and teeth, to protect surrounding arterial tissue from direct contact with bare metal stent. Comprehensive animal studies demonstrated Hydroxyapatite improves the performance of bare metal stents by inhibiting inflammatory responses, a common cause of restenosis, a re-growth of vascular tissue following stent implantation.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid twenty four thousand dollars by MIV Therapeutics Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664